181 related articles for article (PubMed ID: 37525510)
1. Does the advent of depot therapy represent a step change in our understanding of opioid use disorder and its treatment?
Roberts E; Humphreys K
Drug Alcohol Rev; 2024 Jan; 43(1):261-264. PubMed ID: 37525510
[TBL] [Abstract][Full Text] [Related]
2. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
[TBL] [Abstract][Full Text] [Related]
3. The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019-2022: longitudinal sales data analysis.
Lintzeris N; Hayes V; Dunlop AJ
Med J Aust; 2024 Apr; 220(6):339-340. PubMed ID: 38438113
[No Abstract] [Full Text] [Related]
4. Maintenance medication for opiate addiction: the foundation of recovery.
Bart G
J Addict Dis; 2012; 31(3):207-25. PubMed ID: 22873183
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine Treatment for Opioid Use Disorder: An Overview.
Shulman M; Wai JM; Nunes EV
CNS Drugs; 2019 Jun; 33(6):567-580. PubMed ID: 31062259
[TBL] [Abstract][Full Text] [Related]
6. Initial experience with subcutaneous depot buprenorphine in a medically supervised injecting facility.
Weeks A; Cogger S; Clark N
Drug Alcohol Rev; 2021 Nov; 40(7):1354-1355. PubMed ID: 33821545
[No Abstract] [Full Text] [Related]
7. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
[TBL] [Abstract][Full Text] [Related]
8. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
Johnson B; Monwell B; Capusan AJ
Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
[TBL] [Abstract][Full Text] [Related]
9. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.
Dunlop AJ; White B; Roberts J; Cretikos M; Attalla D; Ling R; Searles A; Mackson J; Doyle MF; McEntyre E; Attia J; Oldmeadow C; Howard MV; Murrell T; Haber PS; Lintzeris N
Addiction; 2022 Feb; 117(2):382-391. PubMed ID: 34184798
[TBL] [Abstract][Full Text] [Related]
10. Medication Treatment of Opioid Use Disorder.
Bell J; Strang J
Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
[TBL] [Abstract][Full Text] [Related]
11. Novel forms of injectable buprenorphine and French model of opioid use disorder treatment.
Lapeyre-Mestre M
Therapie; 2020; 75(5):393-395. PubMed ID: 33039103
[No Abstract] [Full Text] [Related]
12. Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study.
Allen E; Samadian S; Altobelli G; Johnson J; Holmwood C
Drug Alcohol Rev; 2023 May; 42(4):791-802. PubMed ID: 36788357
[TBL] [Abstract][Full Text] [Related]
13. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
Tompkins CNE; Neale J; Strang J
J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
[TBL] [Abstract][Full Text] [Related]
14. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
Neale J; Tompkins CNE; Strang J
Drug Alcohol Rev; 2019 Jul; 38(5):510-518. PubMed ID: 31131514
[TBL] [Abstract][Full Text] [Related]
15. Medication-Based Treatment to Address Opioid Use Disorder.
Leshner AI; Dzau VJ
JAMA; 2019 Jun; 321(21):2071-2072. PubMed ID: 31046072
[No Abstract] [Full Text] [Related]
16. Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges.
Arunogiri S; Lintzeris N
J Subst Abuse Treat; 2021 May; 124():108221. PubMed ID: 33303254
[TBL] [Abstract][Full Text] [Related]
17. Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
Soyka M
Pharmacopsychiatry; 2021 Jan; 54(1):18-22. PubMed ID: 33212514
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
[TBL] [Abstract][Full Text] [Related]
19. Low- and very low-dose buprenorphine induction: new(ish) uses for an old(ish) medication?
Weimer MB; Fiellin DA
Addiction; 2022 Jun; 117(6):1507-1509. PubMed ID: 35032081
[No Abstract] [Full Text] [Related]
20. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
